Company intelligence / Profile preview

ProBioPharm

Ownership: Private
Development stage: Other

Overview

ProBioPharm manufactures sorbed probiotics as alternatives to antibiotics for treating intestinal infections. The company positions itself as an innovator in the field of probiotic pharmaceuticals with a focus on manufacturing and commercialization. There are no detailed clinical trial results publicly disclosed.

If considering the broader context from similarly named entities ("ProBio Pharmaceutical"), they claim a portfolio spanning diabetes, oncology, respiratory diseases, cardiology, immunology—but this may refer to a different or related entity.

Therapeutic areas: EndocrinologyInfectious DiseasesOther
Industry: Biotech

Beyond the preview

Go deeper on ProBioPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProBioPharm.

Explore the full profile